Is ASTHENIA a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed ASTHENIA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 154 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported ASTHENIA to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and ASTHENIA. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause ASTHENIA, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes ASTHENIA. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if ASTHENIA ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing ASTHENIA: 154
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where ASTHENIA is a reported side effect: 4.6260%

FDA reports of any drug causing ASTHENIA : 103263
Average percentage for all medicated patients where ASTHENIA is reported as a complication: 0.6472%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with ASTHENIA:

ASPIRIN (9609 patients)
TYSABRI (5909 patients)
FORTEO (5601 patients)
HEPARIN SODIUM INJECTION (5322 patients)
LIPITOR (4985 patients)
VIOXX (4948 patients)
AVONEX (4623 patients)
LASIX (4215 patients)
FOSAMAX (4007 patients)
LISINOPRIL (3935 patients)
PREDNISONE (3902 patients)
SYNTHROID (3682 patients)
HUMIRA (3379 patients)
COUMADIN (3300 patients)
PLAVIX (3248 patients)
NEXIUM (3221 patients)
FUROSEMIDE (3180 patients)
DIGOXIN (3147 patients)
ZOMETA (3086 patients)
ATENOLOL (2931 patients)
OMEPRAZOLE (2796 patients)
SIMVASTATIN (2771 patients)
NEURONTIN (2663 patients)
ZOCOR (2629 patients)
FOLIC ACID (2553 patients)
XANAX (2518 patients)
PRILOSEC (2494 patients)
HYDROCHLOROTHIAZIDE (2483 patients)
CRESTOR (2444 patients)
NORVASC (2401 patients)
PROTONIX (2362 patients)
AMBIEN (2342 patients)
POTASSIUM CHLORIDE (2287 patients)
SEROQUEL (2262 patients)
SANDOSTATIN LAR (2257 patients)
ACETAMINOPHEN (2251 patients)
ZOLOFT (2250 patients)
LEVOTHYROXINE SODIUM (2249 patients)
VITAMIN D (2247 patients)
LYRICA (2227 patients)
BYETTA (2148 patients)
METHOTREXATE (2135 patients)
TOPROL-XL (2126 patients)
PAXIL (2074 patients)
METFORMIN HCL (2035 patients)
ENBREL (2013 patients)
LANTUS (1942 patients)
ALBUTEROL (1924 patients)
REMICADE (1914 patients)
DEXAMETHASONE (1885 patients)
REVLIMID (1873 patients)
ALLOPURINOL (1853 patients)
LEVAQUIN (1852 patients)
CELEBREX (1850 patients)
CYMBALTA (1844 patients)
OXYCONTIN (1829 patients)
PREVACID (1812 patients)
ATIVAN (1807 patients)
CALCIUM (1807 patients)
LORAZEPAM (1759 patients)
WARFARIN SODIUM (1724 patients)
DIOVAN (1702 patients)
METOPROLOL TARTRATE (1684 patients)
COREG (1657 patients)
VICODIN (1652 patients)
GABAPENTIN (1651 patients)
AREDIA (1644 patients)
LEXAPRO (1596 patients)
PREDNISONE TAB (1568 patients)
PERCOCET (1551 patients)
IBUPROFEN (1549 patients)
ZOFRAN (1516 patients)
RIBAVIRIN (1486 patients)
PEGASYS (1433 patients)
CLONAZEPAM (1412 patients)
DECADRON (1392 patients)
ADVAIR DISKUS 100/50 (1376 patients)
INSULIN (1343 patients)
AMLODIPINE (1309 patients)
REBIF (1281 patients)
METOCLOPRAMIDE (1259 patients)
DURAGESIC-100 (1249 patients)
SPIRONOLACTONE (1246 patients)
PREMARIN (1245 patients)
ALPRAZOLAM (1241 patients)
OXYCODONE HCL (1224 patients)
PROZAC (1213 patients)
MULTI-VITAMINS (1202 patients)
AVANDIA (1199 patients)
MULTI-VITAMIN (1198 patients)
MORPHINE (1190 patients)
NITROGLYCERIN (1172 patients)
CHANTIX (1168 patients)
SPIRIVA (1167 patients)
EFFEXOR (1164 patients)
GLUCOPHAGE (1150 patients)
LORTAB (1125 patients)
METOPROLOL (1114 patients)
VITAMIN B-12 (1095 patients)
SINGULAIR (1093 patients)
KLONOPIN (1084 patients)
CARBOPLATIN (1084 patients)
ZYPREXA (1080 patients)
VELCADE (1063 patients)
ZETIA (1059 patients)
REGLAN (1055 patients)
CISPLATIN (1040 patients)
ACTOS (1039 patients)
GLIPIZIDE (1038 patients)
EXJADE (1035 patients)
LOVENOX (1018 patients)
COZAAR (1014 patients)
BETASERON (1011 patients)
TRAMADOL HCL (1008 patients)
CELEXA (1005 patients)
BACLOFEN (999 patients)
DIANEAL (995 patients)
PEG-INTRON (990 patients)
ZANTAC (984 patients)
DIAZEPAM (980 patients)
MAGNEVIST (976 patients)
TRAZODONE HCL (972 patients)
GLYBURIDE (958 patients)
FLUOROURACIL (943 patients)
FLOMAX (942 patients)
PREDNISOLONE (931 patients)
TYLENOL (CAPLET) (930 patients)
SUTENT (926 patients)
HUMALOG (923 patients)
RANITIDINE (922 patients)
COMPAZINE (917 patients)
VALIUM (908 patients)
ASCORBIC ACID (904 patients)
WELLBUTRIN (902 patients)
CLONIDINE (890 patients)
GLEEVEC (889 patients)
ARANESP (889 patients)
ALTACE (886 patients)
PRADAXA (886 patients)
TYLENOL (884 patients)
CARVEDILOL (883 patients)
LOPRESSOR (877 patients)
BENADRYL (872 patients)
RAMIPRIL (872 patients)
MORPHINE SULFATE (866 patients)
CALCIUM CARBONATE (865 patients)
NEXAVAR (863 patients)
VITAMIN E (857 patients)
FENTANYL (856 patients)
RISPERDAL (855 patients)
ALDACTONE (850 patients)
COLACE (847 patients)
ZYRTEC (832 patients)
FLEXERIL (822 patients)
AMOXICILLIN (820 patients)
FISH OIL (796 patients)
POTASSIUM (793 patients)
ENALAPRIL MALEATE (792 patients)
AVELOX (785 patients)
CYCLOPHOSPHAMIDE (782 patients)
PROCRIT (779 patients)
PEPCID (772 patients)
XELODA (771 patients)
TAXOTERE (768 patients)
SOLIRIS (767 patients)
ALLEGRA (766 patients)
HEPARIN SODIUM (764 patients)
ACTONEL (764 patients)
CIPROFLOXACIN (761 patients)
NIASPAN (756 patients)
FERROUS SULFATE TAB (756 patients)
METFORMIN (753 patients)
AMITRIPTYLINE HCL (753 patients)
LEVOXYL (749 patients)
IRON (741 patients)
MIRALAX (736 patients)
NAMENDA (735 patients)
AMIODARONE HCL (731 patients)
EFFEXOR XR (728 patients)
PANTOPRAZOLE (720 patients)
TOPAMAX (716 patients)
DILAUDID (700 patients)
LANSOPRAZOLE (698 patients)
KEPPRA (696 patients)
ARIMIDEX (695 patients)
VYTORIN (691 patients)
BACTRIM (690 patients)
AVASTIN (689 patients)
AMARYL (689 patients)
TRICOR (689 patients)
COPEGUS (682 patients)
THALOMID (676 patients)
LAMICTAL (674 patients)
METOPROLOL SUCCINATE (668 patients)
CARDIZEM (663 patients)
ZITHROMAX (661 patients)
KETEK (658 patients)
TEGRETOL (656 patients)
THALIDOMIDE (655 patients)
GILENYA (655 patients)
KLOR-CON (654 patients)
DEPAKOTE (653 patients)
TAXOL (653 patients)
PROMETHAZINE (651 patients)
ELAVIL (649 patients)
ALENDRONATE SODIUM (646 patients)
FLUCONAZOLE (641 patients)
HYDROCODONE (640 patients)
FLONASE (638 patients)
VERAPAMIL (638 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about ASTHENIA and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.